Neurociencias
Département
JOSE ANGEL
RUIZ ORTEGA
PROFESORADO PLENO
Publications dans lesquelles il/elle collabore avec JOSE ANGEL RUIZ ORTEGA (15)
2023
-
Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment
International Review of Neurobiology (Academic Press Inc.), pp. 103-143
2020
-
Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers
Frontiers in Neuroscience, Vol. 14
2019
-
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation
Neurobiology of Disease, Vol. 121, pp. 252-262
-
Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders
International Review of Neurobiology (Academic Press Inc.), pp. 229-257
2018
-
Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)
Molecular Neurobiology
-
Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212
-
Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299
2017
-
Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors
Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735
2016
-
Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease
Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230
2015
-
Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration
Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858
2014
-
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease
International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687
2013
-
In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190
2009
-
Levodopa-induced dyskinesias in parkinson disease are independent of the extent of striatal dopaminergic denervation: A pharmacological and SPECT study
Clinical Neuropharmacology, Vol. 32, Núm. 6, pp. 326-329
2008
-
Involvement of subthalamic nucleus in the stimulatory effect of Δ9-tetrahydrocannabinol on dopaminergic neurons
Neuroscience, Vol. 151, Núm. 3, pp. 817-823
2006
-
Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: Effects of subthalamotomy and levodopa treatment
Brain Research, Vol. 1084, Núm. 1, pp. 175-184